Skip to main content

Dr. Michaela L. Tsai, MD

Hematology & Oncology (Hematology & Oncology Physician)

1221 Madison St, 2nd Fl
Seattle, WA 98104

Who else practices at this address →

King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas

Call (206) 386-2323

  • Medicare participating

At a glance

Medical school
Harvard Medical School (1995)
Years since graduation
31
In the NPI registry since
2005
Medicare patients seen, 2024
156

Licensed in Washington since 2021, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1995Medical school: Harvard Medical School
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    WA license MD61182267 (first issued 2021; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
156
Services billed
596
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes236110
Established patient office or other outpatient visit, 40-54 minutes7139
Established patient office or other outpatient visit, 20-29 minutes6756
New patient office or other outpatient visit, 60-74 minutes2424

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Anastrozole
Other prescribers in Seattle, WA
188
Tamoxifen Citrate
Other prescribers in Seattle, WA
175
Letrozole
Other prescribers in Seattle, WA
142
Exemestane30
Calquence (acalabrutinib maleate)25
Gabapentin
Other prescribers in Seattle, WA
24
Verzenio (abemaciclib)18
Zarxio (filgrastim-sndz)14
Acyclovir
Other prescribers in Seattle, WA
13
Eliquis (apixaban)
Other prescribers in Seattle, WA
12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $4.13 in total to this clinician.

By company
Pfizer Inc.$4.13
By type
Food and Beverage$4.13

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Washington →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 7 companies. The companies reported $253,554 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
    AstraZeneca Pharmaceuticals LP
  • Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
    AbbVie Inc. · Completed · NCT02947347
  • A phase 1B2 openlabel multicenter dose escalation and dose expansion study to evaluate the safety tolerability pharmacokinetics pharmacodynamics and antitumor activity of PF07220060 in combination with PF07104091 plus…
    Pfizer Inc.
  • CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
    AstraZeneca UK Limited
  • A phase 1 dose escalation and expansion study to evaluate safety tolerability pharmacokinetic pharmacodynamic and antitumor activity of PF07248144 in participants with advanced or metastatic solid tumors
    Pfizer Inc.
  • Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
    Eli Lilly and Company · Active, not recruiting · NCT03155997
  • A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
    Acerta Pharma LLC
  • A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer, Interventional
    Stemline Therapeutics Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Seattle

Sources

NPI registry (CMS NPPES, November 2026; record last updated January 17, 2022), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1801872502. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.